Gene variant linked to effectiveness of plavix
by Anil Kumar

Patients with a certain genetic variation and who received the antiplatelet drug clopidogrel -- Plavix -- had a decreased platelet response to treatment, revealed by researchers.
Researchers at the University of Maryland School of Medicine have identified a common gene variant carried by as many as a third of the general population that is believed to play a major role in determining why people do not respond to a popular anti-clotting medication, Plavix.
If the medication doesn't work, patients are at increased risk for subsequent heart attacks, strokes and other serious cardiovascular problems.
The results of the study, published in the Aug. 26, 2009, issue of the Journal of the American Medical Association (JAMA), confirm a previously reported link between people's decreased response to Plavix, also known as clopidogrel, and common variations of the CYP2C19 gene. The study is the first to identify a common variant of this gene by using a sophisticated technique called a genome-wide association study to rapidly scan hundreds of thousands of genetic markers in the DNA of participants. More than 400 members of the Old Order Amish community in Pennsylvania took part in the study.
"By scanning the entire genome, we found compelling evidence that the CYP2C19 gene is a key determinant of how people respond to this medication," says the lead author, Alan R. Shuldiner, M.D., professor of medicine and director of the Program in Genetics and Genomic Medicine at the University of Maryland School of Medicine in Baltimore. "We didn't detect any other common gene variants that appear to be as significant as CYP2C19, but our research suggests that people's response to clopidogrel is largely inherited and additional common and rare gene variants most likely are involved."
Dr. Shuldiner says he will continue his research to search for these gene variants. "The more we know about how genes affect people's response to medicines, the better able we are to develop effective new therapies and tailor treatment to an individual patient's genetic make-up," he says.
About 30 percent of the general population in the United States has the CYP2C19 variant identified in the study. Dr. Shuldiner says that it can be detected by a simple genetic test using DNA from blood or saliva. "If people have the gene variant, they might need to take a higher dose of clopidogrel or a different medication altogether," he says, adding that more research is needed before such testing becomes routine.
Plavix is one of the world's best-selling medications. It is used to prevent platelets from sticking together and causing blood clots in patients with cardiovascular disease who are at risk of having future heart attacks and strokes.
(Anil Kumar -- sub-editor compiled and published
Gene variant linked to effectiveness of plavix at HealthNewsTrack on August 26, 2009 sourced from University of Maryland Medical Center - http://www.umm.edu/)
Heart disease - recent articles and current news stories:
-
Sugar sweetened drinks may increase heart risk in women-
Financial reimbursement increases cardiac stress tests in patients-
Transcatheter aortic valve replacement TAVR shows superiority in heart patients-
Burmese python heart growth may benefit diseased human heart-
Expandable prosthesis resolves advanced aortic valve diseaseHeart disease article/news source:
Read more health articles from
University of Maryland Medical Center and
health articles from USA.
Heart disease - search related terms:
Anti clotting medication,
Antiplatelet drug,
Clopidogrel,
Gene,
Gene variant,
Heart attack,
Heart disease,
Plavix,
Stroke,
Heart disease books,
Mission
Health Newstrack is dedicated to serve recent and updated health & medical research, events/news, views/reviews to its subscribers and free access to general public, health & medical professionals, and other health seekers worldwide online with a user-friendly system.
Subscribe to Health News by Email
Current news
University of Maryland researchers identify gene variant linked to effectiveness of plavix -- First study to use genome-wide scanning approach to locate gene that affects response to popular anti-clotting medication.
About Heart diseaseHeart disease is the narrowing or blockage of the arteries and vessels that provide oxygen and nutrient-rich blood to the heart. It is caused by atherosclerosis, an accumulation of fatty materials on the inner linings of arteries that restricts blood flow. When the blood flow to the heart is completely cut off, the result is a heart attack because the heart is starved of oxygen.